Ikema：卡非佐米作为复发或难治性多发性骨髓瘤患者首选的伊沙妥昔单抗组合？

{"title":"Ikema：卡非佐米作为复发或难治性多发性骨髓瘤患者首选的伊沙妥昔单抗组合？","authors":"Laura Cailly, X. Leleu, Cécile Gruchet","doi":"10.1684/hma.2021.1691","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":42476,"journal":{"name":"Hematologie","volume":" ","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"IKEMA : le carfilzomib comme l’association à privilégier avec l’isatuximab chez les patients en rechute ou réfractaire d’un myélome multiple ?\",\"authors\":\"Laura Cailly, X. Leleu, Cécile Gruchet\",\"doi\":\"10.1684/hma.2021.1691\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":42476,\"journal\":{\"name\":\"Hematologie\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1684/hma.2021.1691\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1684/hma.2021.1691","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}